Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Amortization of Deferred Charges: 2014-2024

Historic Amortization of Deferred Charges for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $1.0 million.

  • Cidara Therapeutics' Amortization of Deferred Charges rose 13.59% to $326,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 22.05%. This contributed to the annual value of $1.0 million for FY2024, which is 9.50% down from last year.
  • As of FY2024, Cidara Therapeutics' Amortization of Deferred Charges stood at $1.0 million, which was down 9.50% from $1.2 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Amortization of Deferred Charges peaked at $1.2 million during FY2023, and registered a low of -$1.4 million during FY2021.
  • Its 3-year average for Amortization of Deferred Charges is $1.1 million, with a median of $1.0 million in 2024.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first tumbled by 285.73% in 2021, then spiked by 169.13% in 2022.
  • Cidara Therapeutics' Amortization of Deferred Charges (Yearly) stood at $764,000 in 2020, then plummeted by 285.73% to -$1.4 million in 2021, then spiked by 169.13% to $981,000 in 2022, then increased by 18.04% to $1.2 million in 2023, then dropped by 9.50% to $1.0 million in 2024.